Navigation Links
APA resolves to play leading role in improving treatment for gender-variant people
Date:8/17/2008

BOSTON The American Psychological Association urged psychologists today to take a leading role in ending discrimination based on gender identity, calling upon the profession to provide "appropriate, nondiscriminatory treatment to all transgender and gender-variant individuals" and encouraging more research into all aspects of gender identity and expression.

The action came at APA's Annual Convention when the association's governing Council of Representatives adopted a resolution supporting full equality for transgender and gender-variant people. The resolution also calls on APA to:

  • support legal and social recognition of transgender individuals consistent with their gender identity and expression;
  • support the provision of adequate and medically necessary treatment for transgender and gender-variant people;
  • recognize the benefit and necessity of gender transition treatments for appropriately evaluated individuals;
  • call on public and private insurers to cover these treatments.

In addition to adopting the wide-ranging resolution, the Council of Representatives received a report by APA's Task Force on Gender Identity and Gender Variance. The six-member task force spent more than two years reviewing the scientific literature, as well as APA policies regarding transgender issues. It was also charged with developing recommendations for education, professional training and further research into transgenderism, and proposing how APA can best meet the needs of psychologists and students who identify as transgender or gender-variant.

Noting that transgender people, their families, friends and employers are increasingly turning to psychologists for help, "this trend underscores the need for psychologists to acquire greater knowledge and competence in addressing transgender issues," the report states.

Among the report's recommendations:

  • APA should encourage training
    '/>"/>

Contact: Kim I. Mills
kmills@apa.org
202-336-6048
American Psychological Association
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related medicine news :

1. Senetek PLC Resolves Dispute With Marketer of Pyratine-6(TM) on Most Favorable Terms
2. MedImmune Resolves FDA Observations Regarding Manufacturing Process for FluMist(R)
3. UNC study: Two-thirds of severe sports injuries to female students due to cheerleading
4. PSA screening may be biased against obese men, leading to more aggressive cancers
5. Senator Pat Roberts Praised for Leading Successful Effort to Derail $6.2 Million Kansas Medicare Cuts
6. Senator Susan Collins Praised for Leading Successful Effort to Derail $4.3 Million Maine Medicare Cuts
7. Senator Norm Coleman Praised for Leading Successful Effort to Derail $11.4 Million Minnesota Medicare Cuts
8. Senator Elizabeth Dole Praised for Leading Successful Effort to Derail $22.1 Million North Carolina Medicare Cuts
9. Leading Neurosurgical Center in Moscow Purchases CyberKnife System to Expand Ability to Treat Brain and Spinal Tumors
10. Anthem Blue Cross and Blue Shield in Colorado Introduces Industry Leading and Comprehensive Transparency Initiative to Colorado
11. Connextions Cited in Leading Industry Analyst Firm's "Hype Cycle" For Health Care Provider Marketing Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... Healthcare Solutions , the parent ... today announced the appointment of Richard Leonardo to ... position, Leonardo will direct Healthcare Solutions’ national sales ... initiatives. , Recognized in the property and casualty ... more than 20 years of experience in business ...
(Date:6/18/2013)... New York, New York (PRWEB) June 18, 2013 ... forward in both state and federal court, a new report ... of more than 70,000 U.S. Food & Drug Administration (FDA) ... According to NewsChannel5 in Cleveland, Ohio, over 4.700 Mirena ... since 2008, while more than 1,300 have reportedly experienced uterine ...
(Date:6/18/2013)... By studying one of the most successful ... of successful strategies in his article What We Can ... Study. , The inspirational brand Gollan refers to is ... an impressive 62 million followers (and rising). , The ... Facebook Pages earlier this year. The Facebook data tracking publication ...
(Date:6/18/2013)... likely to keep their scheduled medical appointments and ... physician listens, explains things clearly and knows them as ... research suggests. , "If people feel their doctor really ... doctor has their best interests at heart and may ... leader Tabor E. Flickinger, M.D., M.P.H., a fellow in ...
(Date:6/18/2013)... research scientist Daniel Perlman has discovered a way to ... foods that are consumed by humans, potentially opening the ... A U.S. patent (#8,460,738) on the new process and ... Phytosterols in plants and cholesterol molecules in animals are ... are attracted to one another. When they mix in ...
Breaking Medicine News(10 mins):Health News:Healthcare Solutions Appoints Richard Leonardo to Chief Sales Officer 2Health News:Mirena Lawsuit News: Bernstein Liebhard LLP Comments on Mounting Reports of Mirena Side Effects, Including Device Migration, Uterine Perforations 2Health News:Mirena Lawsuit News: Bernstein Liebhard LLP Comments on Mounting Reports of Mirena Side Effects, Including Device Migration, Uterine Perforations 3Health News:Casey Gollan Shows What We Can Learn From One of the Best Facebook Pages There Is 2Health News:Casey Gollan Shows What We Can Learn From One of the Best Facebook Pages There Is 3Health News:Respect may be the key to stopping patient 'no shows' 2Health News:Brandeis scientist invents anti-cholesterol process 2
... to identifying high-risk behaviors among adolescents. Injury risk, ... leading causes of adolescent morbidity and mortality; yet pediatricians ... concerns. That paradox of care is the motivation behind ... Pediatrics, which found adolescents who participated in computerized screening ...
... adults and is emerging in the world of pediatrics. A ... D insufficiency, causes rickets in children and can be treated ... as increased sun exposure. , A new study ... the first study to investigate vitamin D insufficiency in pediatric ...
... 1 Aflac Incorporated,announced today that Martin A. Durant ... chief financial officer. Susan R. Blanck has been,promoted to ... are,effective June 1, 2008., Durant first joined Aflac ... He was with Aflac for 10 years, eventually serving ...
... Prenatal biochemical screening tests are widely used to look ... serious handicap, or even death during gestation or in the ... able to detect fewer than half of the total chromosomal ... conference of the European Society of Human Genetics tomorrow (Monday ...
... of particular gene respond well to targeted therapy , , ... who have the normal version of a particular gene ... that includes adding the targeted therapy Erbitux to chemotherapy. ... normal, or "wild-type" form of the gene, according to ...
... melanoma tumors may make the cancer more vulnerable to chemotherapy, ... Duke Comprehensive Cancer Center. , We tested a compound that ... on the surface of a melanoma cell," said Douglas Tyler, ... Medical Center, and senior investigator on this study. "When chemotherapy ...
Cached Medicine News:Health News:Waiting room gadget may prove to be a life-saver 2Health News:First study to examine vitamin D insufficiency in pediatric patients with low bone density 2Health News:Martin Durant Promoted to Executive Vice President and Deputy CFO; Sue Blanck Promoted to First Senior Vice President of Aflac Japan 2Health News:Martin Durant Promoted to Executive Vice President and Deputy CFO; Sue Blanck Promoted to First Senior Vice President of Aflac Japan 3Health News:Prenatal biochemical screening only detects half of chromosomal abnormalities 2Health News:Prenatal biochemical screening only detects half of chromosomal abnormalities 3Health News:Erbitux Works Well for Two-Thirds of Colon Cancer Patients 2Health News:Erbitux Works Well for Two-Thirds of Colon Cancer Patients 3Health News:Combination therapy packs 1-2 punch against melanoma 2
(Date:6/18/2013)... SYDNEY, Australia And EMERYVILLE, ... Adamas Pharmaceuticals, Inc. presented final results today from ... HCl extended release) capsules demonstrating a statistically significant ... change from baseline at week 8 versus placebo ... is Adamas, investigational extended-release formulation of amantadine intended ...
(Date:6/17/2013)... LOS ANGELES , June 17, 2013 ... TopProdeals.com , a technology platform that connects buyers ... evolved into being an industry leader. ... scenes at TopProdeals™ are intimately familiar with the dental ... the healthcare community and have diligently worked to negotiate ...
(Date:6/17/2013)... SAN DIEGO , June 17, 2013 BioMed ... that its board of directors has declared a second quarter ... dividend is equivalent to an annualized dividend of $0.94 per ... payable on July 15, 2013 to stockholders of record at ... About BioMed Realty Trust BioMed Realty delivers ...
Breaking Medicine Technology:Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 2Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 3Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 4Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 5Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 6TopProdeals.com Rises to Top as Discount Dental Supply Leader 2BioMed Realty Trust Declares Second Quarter 2013 Common Stock Dividend 2BioMed Realty Trust Declares Second Quarter 2013 Common Stock Dividend 3
... WOONSOCKET, R.I., Sept. 19 CVS/pharmacy today,announced that it ... vaccinations in over 4,000 of its stores across the ... on October 1, 2007 and continue,through November. For dates, ... option #1, or visit the CVS.com online Store,Finder to ...
... Targanta Therapeutics Corporation,today released detailed data ... of its lead antibiotic drug candidate, oritavancin, ... of susceptible and resistant strains of,gram- positive ... the 47th,Annual Interscience Conference on Antimicrobial Agents ...
Cached Medicine Technology:CVS/pharmacy Offers Flu Vaccinations in Over 4,000 Stores 2Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria 2Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria 3Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria 4Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria 5
Delicate Desmarres lid retractors, round serrated handle, very thin blades, polished finish, size 1....
2.0 mm cup , straight shaft, Flat handle, length 125.0 mm....
Size 4 - 2.25 mm...
The Storz Protege is an anterior segment unit only....
Medicine Products: